<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03993262</url>
  </required_header>
  <id_info>
    <org_study_id>ZKSJ0120</org_study_id>
    <secondary_id>2019-001423-12</secondary_id>
    <secondary_id>DRKS00017497</secondary_id>
    <nct_id>NCT03993262</nct_id>
  </id_info>
  <brief_title>Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis</brief_title>
  <acronym>Generate-Boost</acronym>
  <official_title>A Multicenter Randomized, Controlled, Double-blinded Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jena University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jena University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Autoimmune Encephalitis is a disorder of the central nervous system caused by bodily&#xD;
      substances, called antibodies. Antibodies normally help the body to prevent infections.&#xD;
      However, in this disorder, the antibodies turn against the body itself and especially against&#xD;
      cells in the brain and disturb the normal brain function. They are therefore called&#xD;
      autoantibodies.&#xD;
&#xD;
      There is no specific therapy for patients with autoimmune encephalitis so far. At the moment,&#xD;
      the symptoms are treated with approved medications such as cortisone and immunotherapies also&#xD;
      used in oncology. These therapies are unspecified and aim to reduce the number of&#xD;
      autoantibodies and to contain the autoimmune process. In this trial we aim to test a new&#xD;
      therapy option: in this therapy the body cells producing autoantibodies will be specifically&#xD;
      targeted by a substance called bortezomib.&#xD;
&#xD;
      The trial addresses patients with severe autoimmune encephalitis. The aim of the trial is to&#xD;
      evaluate the efficacy and safety of bortezomib in patients with severe autoimmune&#xD;
      encephalitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Autoimmune encephalitis is characterized by autoantibodies against neuronal surface antigens&#xD;
      like the NMDA (N-methyl-D-aspartate) receptor or LGI1 (Leucin-rich glioma inactivated protein&#xD;
      1). So far, no specific therapy exists for this disease. Actual treatment includes&#xD;
      combination therapies aiming for a reduction of pathogenic antibodies and containing the&#xD;
      autoimmune process. In first line, patients are treated with plasmapheresis and cortisone. In&#xD;
      second line, Rituximab and/or cyclophosphamide are administered. The response to these&#xD;
      treatments are, however, often delayed and insufficient.&#xD;
&#xD;
      Therefore, we need a specific therapy aiming at the antibody-producing plasma cells.&#xD;
&#xD;
      Bortezomib is a proteasome inhibitor which interferes with NF-kB (nuclear factor kB) and the&#xD;
      ubiquitin proteasome signaling pathway. Bortezomib acts preferably on cells with high protein&#xD;
      synthesis - like plasma cells - and induces cell death in these cells. Bortezomib is used&#xD;
      since more than a decade in chemotherapy of the multiple myeloma. Additionally, it is&#xD;
      reported for systemic autoimmune diseases like lupus erythematodes that bortezomib leads to a&#xD;
      depletion of plasma cells and therefore reduces the number of pathogenic antibodies and&#xD;
      improves clinical outcome. The therapeutic potential of bortezomib for NMDAR encephalitis is&#xD;
      described in a first case series with 5 patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 13, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>1:1 randomization will be done centrally and stratified by site. Block randomization of variable block sizes will be used.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The study drug will be provided blinded by the local pharmacy.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>modified Rankin-Score (mRS)</measure>
    <time_frame>17 weeks after first administration of the study drug</time_frame>
    <description>modified Rankin-Score from 0 = no symptoms to 6 = death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>modified Rankin-Score (mRS)</measure>
    <time_frame>3, 6, 9 and 13 weeks after first administration of the study drug; GCS Score also 17 weeks after first administration of the study drug</time_frame>
    <description>modified Rankin-Score from 0 = no symptoms to 6 = death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of in-hospital stay / length of ICU stay</measure>
    <time_frame>until 17 weeks after first administration of the study drug</time_frame>
    <description>Number of days in hospital or on ICU for each patient from first administration of the study drug until 17 weeks after first administration of the study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune response</measure>
    <time_frame>at study start and 17 weeks after first administration of the study drug</time_frame>
    <description>Antibody titer (in serum and liquor) and cellular immune response (FACS analysis of liquor)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neurocognitive function assessed by Montreal Cognitive Assessment</measure>
    <time_frame>at study start and 17 weeks after first administration of the study medication</time_frame>
    <description>total score of the Montreal Cognitive Assessment (MoCA) (0 to max. 30 points = best possible result)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neurocognitive function assessed by Mini-Mental Status Test</measure>
    <time_frame>at study start and 17 weeks after first administration of the study medication</time_frame>
    <description>total score of the Mini-Mental Status Test (MMST) (0 to max 30 points = best possible result)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neurocognitive function assessed by Rey Auditory Verbal Learning Test</measure>
    <time_frame>at study start and 17 weeks after first administration of the study medication</time_frame>
    <description>total score of the Rey Auditory Verbal Learning Test (RAVLT) (memory performance assessed by 3 word lists which are read to the patient and should be recalled and repeated by the patient; different proceeding for the 3 word lists)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neurocognitive function assessed by Neuropsychiatric Inventory Questionnaire</measure>
    <time_frame>at study start and 17 weeks after first administration of the study medication</time_frame>
    <description>total score of the Neuropsychiatric Inventory Questionnaire (NPI) (0 = best score to max 36 (patient) or 60 (caregiver)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety of Bortezomib regarding polyneuropathy, increase of liver enzymes and secondary infections</measure>
    <time_frame>until 17 weeks after first administration of the study drug</time_frame>
    <description>number of polyneuropathy cases, number of increased liver enzymes, number of secondary infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety of Bortezomib regarding polyneuropathy</measure>
    <time_frame>until 17 weeks after first administration of the study drug</time_frame>
    <description>number of polyneuropathy cases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety of Bortezomib regarding increase of liver enzymes</measure>
    <time_frame>until 17 weeks after first administration of the study drug</time_frame>
    <description>number of increased liver enzyme values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary infections due to Bortezomib</measure>
    <time_frame>until 17 weeks after first administration of the study drug</time_frame>
    <description>number of secondary infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematotoxicity events due to Bortezomib</measure>
    <time_frame>until 17 weeks after first administration of the study drug</time_frame>
    <description>number of hematotoxicity events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal toxicity due to Bortezomib</measure>
    <time_frame>until 17 weeks after first administration of the study drug</time_frame>
    <description>number of gastrointestinal toxicity events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total Glasgow Coma Scale (GCS)</measure>
    <time_frame>3, 6, 9, 13 and 17 weeks after first administration of the study drug</time_frame>
    <description>GCS from 3 to 15 points (sum of 3 subscores eye response (1 to 4 points), motor response (1 to 6 points), verbal response (1 to 5 points); highest score = best score; 1= worst score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Destruction marker UCH-L1 (Ubiquitin carboxy-terminal hydrolase L1) in serum and liquor</measure>
    <time_frame>at baseline visit and 17 weeks after first administration of the study drug</time_frame>
    <description>Analysis of destruction marker UCH-L1 in serum and liquor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Destruction marker Neurofilament light chain (in serum and liquor)</measure>
    <time_frame>at baseline visit and 17 weeks after first administration of the study drug</time_frame>
    <description>Analysis of destruction marker Neurofilament light chain in serum and liquor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Destruction markers GFAP (glial fibrillary acidic protein) in serum and liquor</measure>
    <time_frame>at baseline visit and 17 weeks after first administration of the study drug</time_frame>
    <description>Analysis of destruction marker GFAP in serum and liquor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Destruction marker TAU proteins in serum and liquor</measure>
    <time_frame>at baseline visit and 17 weeks after first administration of the study drug</time_frame>
    <description>Analysis of destruction marker TAU in serum and liquor</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Autoimmune Encephalitis</condition>
  <arm_group>
    <arm_group_label>Interventional</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 to 3 cycles Bortezomib with 1,3mg/m2 body surface s.c. + 20mg dexamethasone p.o. on days 1, 4, 8 and 11 (= 1 cycle)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 to 3 cycles placebo (NaCl solution) s.c. + 20mg dexamethasone p.o. on days 1, 4, 8 and 11 (= 1 cycle)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>1 to 3 cycles Bortezomib with 1,3mg/m2 body surface s.c. + 20mg dexamethasone p.o. on days 1, 4, 8 and 11 (= 1 cycle)</description>
    <arm_group_label>Interventional</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 to 3 cycles placebo (NaCl solution) s.c. + 20mg dexamethasone p.o. on days 1, 4, 8 and 11 (= 1 cycle)</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>isotonic NaCl solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinically diagnosed severe autoimmune encephalitis (defined as mRS ≥ 3) with&#xD;
             autoantibodies to neuronal surface proteins in cerebrospinal fluid and / or serum&#xD;
&#xD;
          -  Pretreatment with rituximab&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  signed informed consent&#xD;
&#xD;
          -  Women of childbearing potential (up to 2 years after menopause): negative pregnancy&#xD;
             test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnancy/breast-feeding&#xD;
&#xD;
          -  acute infiltrative pulmonary and pericardial disease&#xD;
&#xD;
          -  malignant tumor under current chemotherapy&#xD;
&#xD;
          -  Simultaneous participation in another intervention study&#xD;
&#xD;
          -  Previous participation in this study&#xD;
&#xD;
          -  Known hypersensitivity to an ingredient of the investigational product&#xD;
&#xD;
          -  Continued therapy with glucocorticoids / rituximab during the study duration (last&#xD;
             dose must be administered before the first dose of the investigational product)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Geis, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital Jena</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christian Geis, Prof.</last_name>
    <phone>+49 (0) 3641</phone>
    <phone_ext>9323413</phone_ext>
    <email>Christian.Geis@med.uni-jena.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jonathan Wickel, Dr.</last_name>
    <phone>+49 (0) 3641</phone>
    <phone_ext>9323561</phone_ext>
    <email>Jonathan.Wickel@med.uni-jena.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ludwig-Maximilians-Universität München, Klinikum Großhadern</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tania Kümpfel, Prof.</last_name>
      <phone>+49894400</phone>
      <phone_ext>74435</phone_ext>
      <email>tania.kuempfel@med.uni-muenchen.de</email>
    </contact>
    <contact_backup>
      <last_name>Joachim Havla, Dr.</last_name>
      <phone>+49894400</phone>
      <phone_ext>74435</phone_ext>
      <email>joachim.havla@med.uni-muenchen.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <state>Bayern</state>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claudia Sommer, Prof.</last_name>
      <phone>+49931201</phone>
      <phone_ext>23763</phone_ext>
      <email>sommer_c@ukw.de</email>
    </contact>
    <contact_backup>
      <last_name>Kathrin Doppler, PD Dr.</last_name>
      <phone>+49931201</phone>
      <phone_ext>23787</phone_ext>
      <email>doppler_K@ukw.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kurt-Wolfram Suehs, PD Dr.</last_name>
      <phone>+49511532</phone>
      <phone_ext>2495</phone_ext>
      <email>Suehs.Kurt-Wolfram@mh-hannover.de</email>
    </contact>
    <contact_backup>
      <last_name>Martin Stangel, Prof.</last_name>
      <phone>+49511532</phone>
      <phone_ext>6676</phone_ext>
      <email>Stangel.Martin@mh-hannover.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin, Klinik für Neurologie mit Experimenteller Neurologie</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harald Pruess, PD Dr.</last_name>
      <phone>+49 30 450560</phone>
      <phone_ext>560</phone_ext>
      <email>harald.pruess@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Peter Koertvelyessy, Dr.</last_name>
      <phone>+49 30 450560</phone>
      <phone_ext>164</phone_ext>
      <email>p.koertvelyessy@dzne.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Ruhr-Universität Bochum, St. Josef Hospital, Klinik für Neurologie</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilya Ayzenberg, PD Dr.</last_name>
      <phone>+49 234 509</phone>
      <phone_ext>6423</phone_ext>
      <email>Ilya.Ayzenberg@ruhr-uni-bochum.de</email>
    </contact>
    <contact_backup>
      <last_name>Ruth Schneider, Dr.</last_name>
      <phone>+49 234 509</phone>
      <phone_ext>6433</phone_ext>
      <email>ruth.schneider@rub.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen Georg-August-Universität, Klinik für Neurologie</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dirk Fitzner, Dr.</last_name>
      <phone>+49 551 39</phone>
      <phone_ext>65593</phone_ext>
      <email>d.fitzner@med.uni-goettingen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena, Sektion Translationale Neuroimmunologie, Klinik für Neurologie</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Geis, Prof.</last_name>
      <phone>+49-3641</phone>
      <phone_ext>-9323413</phone_ext>
      <email>Christian.Geis@med.uni-jena.de</email>
    </contact>
    <contact_backup>
      <last_name>Jonathan Wickel, Dr.</last_name>
      <phone>+49 3641</phone>
      <phone_ext>9323561</phone_ext>
      <email>Jonathan.Wickel@med.uni-jena.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinik für Neurologie UKSH, Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Leypoldt, PD Dr.</last_name>
      <phone>+49 431 500</phone>
      <phone_ext>16209</phone_ext>
      <email>frank.leypoldt@uksh.de</email>
    </contact>
    <contact_backup>
      <last_name>Klarissa Stuerner, Dr.</last_name>
      <phone>+49 431 500</phone>
      <phone_ext>23816</phone_ext>
      <email>klarissa.stuerner@uksh.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig, Klinik und Poliklinik für Neurologie</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Florian Then Berg, Prof. Dr.</last_name>
      <phone>+49 341972</phone>
      <phone_ext>4320</phone_ext>
      <email>Florian.ThenBergh@medizin.uni-leipzig.de</email>
    </contact>
    <contact_backup>
      <last_name>Lars-Malte Teusser, Dr.</last_name>
      <phone>+49 341972</phone>
      <phone_ext>4320</phone_ext>
      <email>lars-malte.teusser@medizin.uni-leipzig.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mainz, Klinik und Poliklinik für Neurologie</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefan Bittner, Prof.</last_name>
      <phone>+49 6131 17</phone>
      <phone_ext>2805</phone_ext>
      <email>stefan.bittner@unimedizin-mainz.de</email>
    </contact>
    <contact_backup>
      <last_name>Felix Lüssi, PD Dr.</last_name>
      <phone>+49 6131 17</phone>
      <phone_ext>5278</phone_ext>
      <email>felix.luessi@unimedizin-mainz.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster Klinik für Neurologie</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nico Melzer, PD Dr.</last_name>
      <phone>+49 251 8348</phone>
      <phone_ext>188</phone_ext>
      <email>nico.melzer@ukm.de</email>
    </contact>
    <contact_backup>
      <last_name>Sven Meuth, Prof.</last_name>
      <phone>+49 251 8346</phone>
      <phone_ext>187</phone_ext>
      <email>sven.meuth@ukm.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm, Klinik für Neurologie Neurologische Ambulanz</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Lewerenz, PD Dr.</last_name>
      <phone>+49 731 500</phone>
      <phone_ext>63146</phone_ext>
      <email>jan.lewerenz@uni-ulm.de</email>
    </contact>
    <contact_backup>
      <last_name>Mabule Senel, Dr.</last_name>
      <phone>+49 731 077</phone>
      <phone_ext>5265</phone_ext>
      <email>makbule.senel@uni-ulm.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>June 12, 2019</study_first_submitted>
  <study_first_submitted_qc>June 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2019</study_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jena University Hospital</investigator_affiliation>
    <investigator_full_name>Christian Geis</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>autoimmune disease</keyword>
  <keyword>autoimmune encephalitis</keyword>
  <keyword>bortezomib</keyword>
  <keyword>NMDAR</keyword>
  <keyword>LGI1</keyword>
  <keyword>encephalitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Encephalitis</mesh_term>
    <mesh_term>Hashimoto Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>It is not yet decided in which way and which data exactly will be shared with other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

